rs1463038513
|
|
|
0.020 |
GeneticVariation |
BEFREE |
To determine whether the excess of colon cancer in some breast-ovarian cancer families is related to the I1307K mutation, we evaluated 264 Ashkenazi Jews from 158 families.
|
9407954 |
1997 |
rs1456079929
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To assess whether the progesterone receptor (PR) exon 4 valine to leucine amino acid variant is associated with specific tumour characteristics or with overall risk of ovarian cancer, we examined 551 cases of epithelial ovarian cancer and 298 unaffected controls for the underlying G-->T nucleotide substitution polymorphism.
|
11323389 |
2001 |
rs1516982
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13.
|
22235027 |
2012 |
rs2072590
|
|
|
0.720 |
GeneticVariation |
BEFREE |
To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13.
|
22235027 |
2012 |
rs10088218
|
|
|
0.710 |
GeneticVariation |
BEFREE |
To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13.
|
22235027 |
2012 |
rs2363956
|
|
|
0.710 |
GeneticVariation |
BEFREE |
To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13.
|
22235027 |
2012 |
rs2665390
|
|
|
0.710 |
GeneticVariation |
BEFREE |
To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13.
|
22235027 |
2012 |
rs10098821
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13.
|
22235027 |
2012 |
rs3814113
|
|
|
0.720 |
GeneticVariation |
BEFREE |
To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13.
|
22235027 |
2012 |
rs80358721
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three ovarian cancer cell lines (PEO1, PEO4, and PEO6) were derived from a BRCA2 mutation [5193C>G (Y1655X)] carrier with ovarian carcinoma with acquired cisplatin resistance and a secondary BRCA2 mutation [5193C>T (Y1655Y)] that canceled the inherited mutation.
|
19654294 |
2009 |
rs587782818
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three novel protein-truncating mutations, c.204T>A, c.225T>G, and c.701C>G, were identified. c.204T>A was found in one out of 22 (4.5 %) early-onset (≤45 years of age) ovarian cancer patients and c.225T>G in one out of 119 (0.8 %) patients from breast cancer only families. c.701C>G was found in a 60-year-old control with no family history of breast/ovarian cancer.
|
24800917 |
2014 |
rs190900046
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three novel protein-truncating mutations, c.204T>A, c.225T>G, and c.701C>G, were identified. c.204T>A was found in one out of 22 (4.5 %) early-onset (≤45 years of age) ovarian cancer patients and c.225T>G in one out of 119 (0.8 %) patients from breast cancer only families. c.701C>G was found in a 60-year-old control with no family history of breast/ovarian cancer.
|
24800917 |
2014 |
rs11084033
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This finding is consistent with bioinformatic analysis predicting the rs11084033 rare allele to be responsible for the loss of a confirmed androgen response element, and with published expression data suggesting that aggressive ovarian cancers show decreased KLK3 tumor expression.
|
21787114 |
2011 |
rs3737787
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This study was supposed to investigate the correlation between the functional single nucleotide polymorphisms (SNPs) (rs2516839 and rs3737787) in USF1 gene and the efficacy and safety of paclitaxel-based chemotherapy and prognosis in the treatment of ovarian cancer (OC).
|
29322800 |
2019 |
rs1800449
|
|
|
0.020 |
GeneticVariation |
BEFREE |
This study suggests that LOX G473A polymorphism is a new risk factor for ovarian cancer and that LOX protein might be a possible therapeutic target in ovarian cancer.
|
22906264 |
2012 |
rs56307747
|
|
|
0.020 |
GeneticVariation |
BEFREE |
This study suggests that LOX G473A polymorphism is a new risk factor for ovarian cancer and that LOX protein might be a possible therapeutic target in ovarian cancer.
|
22906264 |
2012 |
rs25487
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This study indicated that XRCC1 Arg194Trp, Arg280His, and Arg399Gln did not affect OS after platinum-based chemotherapy in OC patients.
|
30407287 |
2018 |
rs1271572
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This pooled analysis suggests that rs1271572 might influence the risk of ovarian cancer, in particular among younger women.
|
21673961 |
2011 |
rs2228570
|
|
|
0.050 |
GeneticVariation |
BEFREE |
This pooled analysis provides further evidence that the VDR rs2228570 polymorphism might influence ovarian cancer susceptibility.
|
20473893 |
2011 |
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This meta-analysis supports an association between MTHFR C677T</span> polymorphism and ovarian cancer risk, and there might be a race-specific effect in this association.
|
23329275 |
2013 |
rs1042838
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This meta-analysis suggests that the two polymorphisms of PGR, Alu insertion and Val660Leu, may contribute to ovarian cancer susceptibility as low-penetrance risk factors.
|
25228088 |
2015 |
rs137853011
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This karyotype phenotype was not observed in other tested tissues or in an ovarian cancer patient with a different homozygous missense mutation in <i>CHEK2</i> (c.1283C>T; p.Ser428Phe).
|
30858171 |
2019 |
rs748876625
|
|
|
0.020 |
GeneticVariation |
BEFREE |
This finding indicates the necessity of searching for 300T>G mutation in families with a single diagnosis of ovarian cancer in family.
|
22395474 |
2012 |
rs121434592
|
|
|
0.030 |
GeneticVariation |
BEFREE |
They described a novel point mutation (E17K) in the pleckstrin homology domain (PHD) of the AKT1 gene in human breast, colorectal and ovarian cancers, and demonstrated that it induces leukemia in mice.
|
17921701 |
2007 |
rs387906659
|
|
|
0.020 |
GeneticVariation |
BEFREE |
They described a novel point mutation (E17K) in the pleckstrin homology domain (PHD) of the AKT1 gene in human breast, colorectal and ovarian cancers, and demonstrated that it induces leukemia in mice.
|
17921701 |
2007 |